AHA announces late-breaking lineup to be presented at 2024 Scientific Sessions
Click Here to Manage Email Alerts
Key takeaways:
- The AHA announced its lineup of eight late-breaking sessions to be presented at its upcoming scientific sessions.
- The in-person-only meeting will be held in Chicago from Nov. 16 to 18.
The American Heart Association Scientific Sessions will be held in-person only in Chicago from Nov. 16 to 18 and will feature eight late-breaking science sessions during the 3-day meeting.
The AHA announced the following late-breaking science lineup for its annual meeting.
Late-Breaking Science 1: Celebrating a Century of Cardiovascular Science — From Prevention to Treatment, to Cure:
- effects of intensive BP control in patients with diabetes: the BPROAD trial;
- tirzepatide (Zepbound, Eli Lilly) for patients with HF with preserved ejection fraction and obesity: the SUMMIT trial; and
- nexiguran ziclumeran (nex-z or NTLA-2001, Intellia Therapeutics), in vivo CRISPR-based therapy for patients with transthyretin amyloidosis with cardiomyopathy: interim report of the phase 1 study.
Late-Breaking Science 2: Redefining Arrhythmia Treatment — Pushing Boundaries:
- catheter ablation vs. antiarrhythmic drugs for ventricular tachycardia in ischemic cardiomyopathy: the VANISH2 trial;
- left atrial appendage closure with oral anticoagulation after catheter ablation for atrial fibrillation: the OPTION trial; and
- a randomized trial of anticoagulation for the prevention of ischemic stroke and neurocognitive impairment in AF: the BRAIN AF trial.
Late-Breaking Science 3: Smart Cardiology — Harnessing AI and Innovation for Better Heart Health:
- evaluation of randomized audit and feedback to increase HF treatment optimization among primary care pharmacists in the Veterans Affairs health care system: the PHARM-HF A&F study;
- noninvasive AI to assess intracardiac filling pressure: the SEISMIC-HF I study;
- AI-based automated echocardiographic measurements and the workflow of sonographers: the AI-ECHO study (accepted, not confirmed at time of publication); and
- complete AI-enabled echocardiography interpretation with multitask deep learning: the PanEcho trial.
Late-Breaking Science 4: From Intervention to Prevention — Advances in Coronary and Valvular Heart Disease:
- a randomized clinical trial of restrictive vs. liberal oxygenation in patients undergoing CABG or aortic valve replacement: the GLORIOUS trial;
- a randomized clinical trial of a GLP-1 agonist in patients undergoing CABG or aortic valve replacement : the GLORIOUS trial;
- efficacy and safety of edoxaban (Savaysa, Daiichi Sankyo) in anticoagulant therapy early after surgical bioprosthetic valve replacement: the ENBALV trial; and
- a randomized controlled trial of colchicine vs. placebo and spironolactone vs. placebo in patients with MI: the CLEAR SYNERGY (OASIS 9) trial.
Late-Breaking Science 5: Innovation in Prevention and Global Implementation:
- a randomized trial of BP treatment optimization with single-pill combinations in India: the TOPSPIN trial;
- electronic nudges to increase influenza vaccination among more than 2 million patients with prior MI: the NUDGE-FLU trial;
- a randomized controlled trial of a decision support system to aid physician optimization of early lipid-lowering therapies after ACS: the ZODIAC trial; and
- a randomized trial of new vs. reconditioned pacemakers for patients unable to obtain a new device living in low- and middle-income countries: the My Heart Your Heart (MHYH) trial.
Late-Breaking Science 6: Building on the 4 Pillars — Novel Trials of Medical Therapy for Heart Failure:
- myeloperoxidase inhibition with mitiperstat (AstraZeneca) in HF with preserved and mildly reduced EF: the ENDEAVOR trial;
- a randomized trial of sacubitril/valsartan (Entresto, Novartis) for prevention of cardiotoxicity in high-risk patients undergoing anthracycline chemotherapy: the SARAH trial;
- bumetanide nasal spray demonstrates safety, tolerability and equivalent efficacy compared with IV and oral bumetanide; the RSQ-777-02 trial; and
- a randomized trial of sodium zirconium cyclosilicate and mineralocorticoid receptor antagonist optimization among patients with HFrEF and hyperkalemia: the REALIZE-K trial.
Late-Breaking Science 7: Revolutionizing AF Management — Cutting-Edge Approaches:
- linear ablation plus pulmonary vein isolation (PVI) vs. PVI alone for persistent AF: the PROMPT-AF trial
- a randomized trial of cryoballoon vs. radiofrequency ablation in patients with persistent AF: the CRRF-PeAF trial;
- a randomized controlled trial of metformin and lifestyle/risk factor modification for prevention of AF progression: the TRIM-AF trial; and
- a randomized trial of aggressive risk factor reduction modification for AF: the ARREST-AF trial (accepted, not confirmed at time of publication).
Late-Breaking Science 8: New Targets and New Treatments — Advances in Lipid Therapeutics:
- a phase 2 trial of zerlasiran (Silence Therapeutics), a short-interfering RNA targeting lipoprotein(a), over 60 weeks: the ALPACAR trial;
- a randomized phase 2 trial of muvalaplin (Eli Lilly), an oral disrupter of the assembly of Lp(a): the KRAKEN trial; and
- the safety and efficacy of obicetrapib (NewAmsterdam Pharma) in patients with heterozygous familial hypercholesterolemia: the BROOKLYN trial.
Healio | Cardiology Today will be on-site in Chicago to report the latest news from the AHA Scientific Sessions, with physician perspective, researcher interviews and more. Follow our breaking updates here and by following @CardiologyToday on X (Twitter).
Click Here to Manage Email Alerts